Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation

The Lancet Child & Adolescent Health
Giuseppe PlazziEmmanuel Mignot

Abstract

Narcolepsy is a lifelong neurological disorder with onset commonly in childhood or adolescence. No drugs are indicated for cataplexy and excessive daytime sleepiness in paediatric patients with narcolepsy. Sodium oxybate is approved for use in adult patients with excessive daytime sleepiness or cataplexy, or both, in narcolepsy. We aimed to examine the safety and efficacy of sodium oxybate oral solution treatment in children and adolescents who have narcolepsy with cataplexy. This was a prospective, double-blind, placebo-controlled, randomised-withdrawal, multisite study and open-label investigation done at 30 sites in five countries (USA, Finland, France, Italy, and the Netherlands). Eligible participants were aged 7-16 years at screening, had narcolepsy with cataplexy, and were either being treated with sodium oxybate or were sodium oxybate-naive at entry. Sodium oxybate-naive participants were titrated to an optimal dose. Participants were randomly assigned (1:1) with a dynamic randomisation algorithm to receive placebo or to remain on sodium oxybate for 2 weeks; they then entered an open-label sodium oxybate treatment period for a total study duration of up to 1 year. Random assignment to placebo was discontinued if early e...Continue Reading

Citations

May 29, 2019·Expert Opinion on Pharmacotherapy·Vivien C Abad
Jan 31, 2020·Current Treatment Options in Neurology·Maria Pia GiannoccaroFabio Pizza
Mar 14, 2020·Clinical Pediatrics·Judith A OwensMiriam Weiss
Oct 22, 2019·Therapeutic Advances in Neurological Disorders·Lucie Barateau, Yves Dauvilliers
Sep 18, 2020·Expert Opinion on Pharmacotherapy·Stefano de BiaseMariarosaria Valente
Jul 22, 2019·Nature Reviews. Neurology·Claudio L A BassettiYves Dauvilliers
Aug 9, 2020·Nature and Science of Sleep·Emily C BarkerKatherine M Sharkey
Dec 29, 2018·Expert Opinion on Pharmacotherapy·Stefano de BiaseMariarosaria Valente
Nov 13, 2019·Current Treatment Options in Neurology·Laura Pérez-Carbonell
Aug 7, 2020·Continuum : Lifelong Learning in Neurology·Amy Licis
Jan 4, 2021·Sleep·Virginia PonzianiGiuseppe Plazzi
Feb 27, 2021·Clinical Therapeutics·David SeidenJordan Dubow
Apr 23, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Christian FranceschiniGiuseppe Plazzi
Mar 30, 2021·Acta Psychiatrica Scandinavica·Cyril HaninClaudine Laurent-Levinson
May 23, 2021·Pediatric Pulmonology·Thomas J Dye, Narong Simakajornboon
May 20, 2021·Nature and Science of Sleep·Maria Pia GiannoccaroFabio Pizza
Jun 27, 2021·Journal of Sleep Research·Claudio L A BassettiGert J Lammers
Jun 27, 2021·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Claudio L A BassettiGert J Lammers
Jul 1, 2021·Biopharmaceutics & Drug Disposition·Vivian Rodriguez-CruzMarilyn E Morris
Sep 22, 2021·Journal of Sleep Research·Russell RosenbergJed Black
Sep 1, 2018·The Lancet Child & Adolescent Health·Catherine M Hill
Dec 20, 2018·Lancet Neurology·Fulong XiaoFang Han

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here